Short stature by mutant growth hormones

Area of Science:

• Endocrinology
• Genetics
• Molecular Biology

Background:

• Short stature is often associated with impaired growth hormone (GH) effects, but the molecular underpinnings of bioinactive GH have remained largely elusive.
• Previous case reports suggested biologically inactive GH as a cause of short stature, yet lacked definitive molecular evidence.
• Low insulin-like growth factor-I (IGF-I) levels with normal or high GH concentrations indicate a potential GH signaling defect.

Observation:

• Two novel point mutations (D112G and R77C) were identified in the GH1 gene of children with short stature and presumed bioinactive GH.
• The D112G mutant GH demonstrated an inability to signal GH receptor dimerization, thereby failing to transduce GH-dependent signals.
• The R77C mutant GH exhibited a dual action: it failed to induce tyrosine phosphorylation independently and antagonized the activity of wild-type GH.

Findings:

• The study provides the first molecular proof for the mechanism of bioinactive GH syndrome.
• Mutant GH variants, such as D112G and R77C, disrupt critical GH signaling pathways.
• The identified mutations lead to distinct molecular defects, including impaired receptor dimerization and antagonistic effects on wild-type GH.

Implications:

• Understanding the molecular basis of bioinactive GH syndrome allows for accurate diagnosis and potential therapeutic strategies.
• The molecular heterogeneity of GH mutations correlates with diverse clinical presentations and responses to GH therapy.
• This research opens avenues for investigating other genetic causes of growth hormone insensitivity and short stature.